Federal health officials on Thursday backed the public health benefits of nicotine pouches, authorizing Philip Morris International’s Zyn to help adult smokers cut back or quit cigarettes.

Nicotine pouches are a newer class of smokeless products that don’t contain tobacco. Zyn became the first FDA-authorized brand on Jan. 16.

FDA authorizes Zyn nicotine pouches, citing public health benefits for adult smokers, despite concerns over flavored products' appeal to teens.

Officials proposed limiting the amount of nicotine to make cigarettes less addictive, but it's unclear if the incoming administration will offer support.

The FDA authorized the marketing of 20 Zyn products on Thursday, marking the first allowance for the fast-growing nicotine pouches.

The Food and Drug Administration (FDA) announced on Thursday that it authorized the marketing of Zyn nicotine pouches but will be "closely monitoring youth use." Newsweek reached out to Zyn for comment.

Zyn and the retailers who sell the product have run afoul of regulators in recent years. The FDA in April of last year warned 119 retailers to stop selling Zyn to underage people, and the company was ordered to pay $1.2 million last year for violating Washington, D.C.’s smokeless tobacco ban.

The U.S. Food and Drug Administration on Thursday okayed the marketing of 20 Zyn nicotine pouch products after undertaking an extensive scientific review of them.

Health experts are cheering a move by outgoing President Joe Biden. But, this is terrible news if you're a smoker living in New York.

A new FDA proposal would reduce the amount of feel-good nicotine in cigarettes to near-inconsequential levels.

The Food and Drug Administration (FDA) has announced a groundbreaking proposal to drastically reduce nicotine levels in cigarettes, aiming to curb addiction and encourage smokers to switch to less harmful alternatives or quit altogether.